日韩精品久久一区二区三区_亚洲色图p_亚洲综合在线最大成人_国产中出在线观看_日韩免费_亚洲综合在线一区

Global EditionASIA 中文雙語Fran?ais
China
Home / China / Health

China approves its fourth COVID-19 vaccine for emergency use

By Zhang Zhihao | chinadaily.com.cn | Updated: 2021-03-16 15:05
Share
Share - WeChat
[Photo/Institute of Microbiology of the Chinese Academy of Sciences]

China approved a recombinant protein subunit vaccine against COVID-19 for emergency use on Wednesday, according to the vaccine's developer, the Institute of Microbiology of the Chinese Academy of Sciences. 

So far, the vaccine is the fourth approved by the country for emergency use against COVID-19.

The vaccine was developed by the institute and Anhui Zhifei Longcom Biopharmaceutical. It is currently in phase-three clinical trials in foreign countries including Uzbekistan, Pakistan, Ecuador and Indonesia, with plans to inoculate a total of 29,000 volunteers, the institute said in a statement on Monday.

On March 1, Uzbekistan's Ministry of Innovative Development said it has approved the vaccine for market use in the Central Asian nation under the name ZF-UZ-VAC2001. The vaccine was approved for emergency use in the country on Feb 22, making it the world's first recombinant subunit vaccine to be authorized for clinical use. 

Rather than injecting a whole inactivated pathogen to trigger an immune response like previously approved vaccines, subunit protein vaccines contain purified pieces of the virus's protein to train the immune system. These fragments are incapable of causing disease, thus making this type of vaccines very safe.

Notable subunit vaccines include the vaccine for hepatitis B. This type of vaccine does not require high biosecurity labs to make, has high output and low storage requirements, the institute said.

The vaccine completed phase one and two clinical trials in October, and there were no severe adverse effects recorded, the institute said, adding the protection rate for this vaccine is on par with other COVID-19 recombinant subunit and mRNA vaccines in the world, though it did not disclose efficacy details.

US biotech company Novavax is the maker of another recombinant nanoparticle subunit vaccine for COVID called NVX-CoV2373, whose phase-three trials results released last week showed it was 96.4 percent effective against mild, moderate and severe disease caused by the original COVID-19 strain. The mRNA vaccines, developed by Pfizer and Moderna, both have a protection rate of around 95 percent.

Top
BACK TO THE TOP
English
Copyright 1995 - . All rights reserved. The content (including but not limited to text, photo, multimedia information, etc) published in this site belongs to China Daily Information Co (CDIC). Without written authorization from CDIC, such content shall not be republished or used in any form. Note: Browsers with 1024*768 or higher resolution are suggested for this site.
License for publishing multimedia online 0108263

Registration Number: 130349
FOLLOW US
 
主站蜘蛛池模板: 免费的黄网站男人的天堂 | 香港午夜三级a三级高清观看 | 久久国产资源 | 国产九九视频在线观看 | 91精品电影| 国产人妖一区 | 日韩亚洲视频 | 欧美久草 | 亚洲激情视频 | 国产精品成人免费观看 | 国产欧美日韩一区二区三区四区 | 青青在线香蕉精品视频免费看 | 狠狠干夜夜撸 | 国产精品69人妻无码久久久 | 7777精品伊人久久久大香线蕉 | 欧美一级艳片视频免费观看 | 九色视频网址 | 久久er视频 | 理论片午午伦夜理片在线播放 | 日韩成人精品在线 | 亚洲国产日韩欧美综合久久 | 欧美黄色免费网站 | 国产亚洲精品久久无亚洲 | 9色在线 | 国产亚洲女人久久久久久 | 欧美亚洲欧美区 | 综合二区 | 99热综合在线 | 久久vs国产综合色大全 | 三级 在线播放 | 日韩在线视频在线观看 | 国产日韩欧美久久久 | 日韩成人影院 | 天天噜天天干 | 成人免费在线电影 | 精品国产一区二区国模嫣然 | 剑来在线观看 | 亚洲品质自拍视频网站 | 久久国内精品视频 | 久草网站| 秋霞影院精品久久久久 |